Overview

Efficacy Study of Vx001 Vaccine in NSCLC Patients

Status:
Completed

Trial end date:
2017-01-01

Target enrollment:

Participant gender:

Summary

Patients with stage IV or recurrent stage I-III NSCLC with documented disease control (objective response or stable disease) within 3 weeks after platinum based 1st line chemotherapy; only HLA-A*0201 positive patients with TERT expressing tumors will be included. The objective of the trial is survival rate at 12 months.

Phase:

Phase 2

Details

Lead Sponsor:

Vaxon Biotech

Treatments:

Vaccines